Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
MEDI-7352 by AstraZeneca for Diabetic Neuropathic Pain: Likelihood of Approval
MEDI-7352 is under clinical development by AstraZeneca and currently in Phase II for Diabetic Neuropathic Pain. According to GlobalData, Phase...
Data Insights
Risk adjusted net present value: What is the current valuation of AstraZeneca's MEDI-7352?
MEDI-7352 is a monoclonal antibody commercialized by AstraZeneca, with a leading Phase II program in Diabetic Neuropathic Pain. According to...